A composition containing spirothracenyl and its preparation method and application

Abstract

The present application relates to the technical field of pesticides, and specifically discloses a composition containing spirothiazolin and its preparation method and application. A composition containing spirothiazolin and its preparation method and application include the following raw materials in parts by mass: 25-28 parts of active ingredients, 90-95 parts of water, 2-6 parts of dispersants, 0.1-0.5 parts of thickeners, 0.1-0.5 parts of defoamers, 0.1-0.3 parts of preservatives, the active ingredient is an active ingredient microcapsule coated with a modified sodium alginate layer, the capsule wall of the active ingredient microcapsule is PHBV, and the capsule core is an active ingredient, and the active ingredient includes spirothiazolin, abamectin and fluopicolide;In addition, the preparation method of the present application has the advantages of improving drug efficacy, reducing environmental pollution, and extending storage and action time.

Description

Technical Field

[0001] The present application relates to the technical field of insecticides, and more specifically, to a composition containing spirothiocarbamate, a preparation method thereof, and an application thereof. Background Art

[0002] Currently, control of cucumber root-knot nematode disease primarily relies on traditional chemical insecticides, such as organophosphates and carbamate compounds. While these agents can effectively control pests in the short term, long-term use leads to significant development of pest resistance, resulting in a gradual decline in control effectiveness. Furthermore, traditional insecticides are commonly associated with high toxicity and high residue levels, posing a threat not only to ecological and environmental safety but also to human health through the food chain. With increasingly stringent global environmental regulations and increasing consumer demand for agricultural product safety, the development of new, highly effective, low-toxic, and environmentally friendly pesticides has become an urgent need within the industry.

[0003] Currently, there are three main types of solutions available for controlling root-knot nematodes on the market: single chemical insecticides such as avermectin, which offer the advantage of rapid effectiveness, but their effectiveness decreases by over 40% after two to three seasons of continuous use. Biological agents such as Paecilomyces lilacinus are environmentally friendly, but their effectiveness is unstable and significantly affected by temperature and humidity. Third, combination chemical pesticides such as thiazolinone and avermectin can delay the development of resistance but carry a 10%-15% risk of crop damage. Other alternatives, such as the soil fumigant chloropicrin, are broad-spectrum and highly effective, but are highly hazardous to use and can damage soil microbial communities. Summary of the Invention

[0004] In order to improve drug efficacy, reduce environmental pollution and prolong storage and action time, the present application provides a composition containing spironolactone and its preparation method and application.

[0005] In the first aspect, the present application provides a composition containing spironolactone and a preparation method and application thereof, using the following technical solution:

[0006] A spirotriazole-containing composition, a preparation method thereof, and an application thereof, comprises the following raw materials in parts by mass: 25-28 parts of an active ingredient, 90-95 parts of water, 2-6 parts of a dispersant, 0.1-0.5 parts of a thickener, 0.1-0.5 parts of a defoaming agent, and 0.1-0.3 parts of a preservative. The active ingredient is an active ingredient microcapsule coated with a modified sodium alginate layer, the capsule wall of the active ingredient microcapsule is PHBV, and the capsule core is the active ingredient, wherein the active ingredient comprises spirotriazole, abamectin, and fluopicolide.

[0007] By adopting the above technical solution, the use of spirothiazolinone, also known as dispirothiazolinone, in combination with abamectin and fluopicolide can improve the insecticidal efficiency and insecticidal effect, and at the same time avoid the situation where pests develop drug resistance due to the use of a single drug. PHBV has good coating and stability. After the active ingredient is coated, it can achieve the effect of oxygen and water isolation, and at the same time can achieve a light-shielding effect to a certain extent, thereby extending the storage time of the composition. After the composition is applied to the field, the modified sodium alginate layer is first degraded for short-term insecticide, and the active ingredient microcapsules are retained to continue to slowly release the active ingredient, and long-term insecticide is carried out in the field, reducing the number of applications, extending the action time, and reducing environmental pollution. The modified sodium alginate layer has good hydrophilicity, which can improve the dispersion and suspension properties of the active ingredient in the composition, which is conducive to extending the storage time of the composition.

[0008] Preferably, in the active ingredients, the mass ratio of spironolactone, abamectin and fluopicolide is (1.12-1.28):(0.67-0.81):(0.95-1.21).

[0009] By adopting the above technical solution, the mass ratio of spirotrichlorf, abamectin and fluopicolide is controlled, so that the active ingredient formed by the combination of the three has higher insecticidal efficiency and insecticidal effect, while reducing the occurrence of pests developing drug resistance.

[0010] Preferably, the method for preparing the active ingredient microcapsules comprises the following steps: dissolving PHBV and the active ingredient in chloroform, adding the mixture to water containing an emulsifier while stirring, stirring and emulsifying, centrifuging, separating, washing, and freeze-drying to obtain the active ingredient microcapsules.

[0011] By adopting the above technical solution, PHBV and the active ingredient have good solubility in the organic solvent chloroform, and can form a uniform solution. When added to the aqueous phase, microcapsules with a core-shell structure are formed. After the organic solvent chloroform is evaporated, active ingredient microcapsules capable of sustained-release of the active ingredient are prepared.

[0012] Preferably, the mass ratio of PHBV to active ingredient is (8.68-9.21):(2.32-2.68).

[0013] By adopting the above technical solution, the mass ratio of PHBV to active ingredient is controlled, thereby effectively improving the encapsulation rate of the active ingredient, so that the active ingredient microcapsules are loaded with more active ingredients, which is beneficial to long-term pest control in the field, prolongs the action time of a single application, and reduces the number of applications.

[0014] Preferably, the preparation method of the active ingredient comprises the following steps: dissolving sodium alginate in water to form a sodium alginate solution, adding the active ingredient and nano-titanium dioxide and dispersing them evenly to form a mixed solution, adding active ingredient microcapsules and stirring them evenly, centrifuging and separating them, dispersing them into a calcium chloride solution, stirring them for 30 minutes, standing them for 1 hour, centrifuging, separating them, and freeze-drying them to obtain the active ingredient.

[0015] By adopting the above technical solution, the modified sodium alginate layer contains active ingredients and nano-titanium dioxide. When the modified sodium alginate layer decomposes in the field, the active ingredients are released to immediately kill and control insects on crops. Nano-titanium dioxide can improve the UV resistance of the modified sodium alginate layer, thereby reducing the photolysis of the active ingredients and the active ingredient microcapsules, so that the active ingredients can fully exert their effectiveness in the field.

[0016] Preferably, the added amount of the active ingredient is 12.15-16.25 wt % of the sodium alginate, and the added amount of nano-titanium dioxide is 2.25-4.12 wt % of the sodium alginate.

[0017] By adopting the above technical solution, the addition amounts of active ingredients and nano-titanium dioxide are controlled, so that the active ingredients can be effectively dispersed in the modified sodium alginate layer. At the same time, the nano-titanium dioxide can not only effectively improve the protective effect of the modified sodium alginate layer on the active ingredients, but also be evenly dispersed in the modified sodium alginate layer.

[0018] Preferably, before adding the active ingredient microcapsules, a silane coupling agent is further added to the mixed solution, and the amount of the silane coupling agent added is 10.32-12.58 wt % of the mixed solution.

[0019] By adopting the above technical solution, the addition of the silane coupling agent can improve the dispersibility of the active ingredient microcapsules in the mixed solution, and as a coupling agent, it can improve the coating effect of the modified sodium alginate layer on the active ingredient microcapsules, as well as the degree of bonding between the modified sodium alginate layer and the active ingredient microcapsules.

[0020] In a second aspect, the present application provides a method for preparing a composition containing spironolactone, using the following technical solution:

[0021] A method for preparing a composition containing spirotriazolyl comprises the following steps: adding a dispersant and a preservative to water, stirring the mixture evenly, adding an active ingredient, dispersing the mixture evenly, adding a thickener and a defoaming agent, and continuing stirring until the mixture is evenly mixed to obtain the composition containing spirotriazolyl.

[0022] By adopting the above technical solution, an aqueous suspension containing active ingredients as the main component is prepared. Using water as a solvent reduces pollution and toxicity to the environment, and the particle size of the active ingredients is small, so they can adhere well to crops when used and exert their insecticidal effect.

[0023] In a third aspect, the present application provides a composition containing spirothiocarbamate for use in preventing and treating cucumber root-knot nematode disease.

[0024] By adopting the above technical solution, the obtained composition containing spirothracenacetyl has a good prevention and control effect on preventing and controlling cucumber root knot nematode disease.

[0025] In summary, this application has the following beneficial effects:

[0026] 1. Since the present application adopts the combination of spirothiocarb, avermectin and fluopicolide to improve the insecticidal efficiency and insecticidal effect, and at the same time avoid the situation where pests develop drug resistance due to the use of a single drug. PHBV has good coating and stability. After the active ingredient is coated, it can achieve the effect of oxygen and water isolation, and at the same time can achieve a certain degree of light-shielding effect, thereby extending the storage time of the composition. After the composition is applied to the field, the modified sodium alginate layer is first degraded for short-term insecticide, and the active ingredient microcapsules continue to slowly release the effective ingredient for long-term insecticide in the field, reducing the number of applications, extending the action time, and reducing environmental pollution. The modified sodium alginate layer has good hydrophilicity, which can improve the dispersion and suspension properties of the active ingredient in the composition, which is conducive to extending the storage time of the composition.

[0027] 2. The modified sodium alginate layer in this application contains active ingredients and nano-titanium dioxide. When the modified sodium alginate layer decomposes in the field, the active ingredients are released to immediately kill and control insects on crops. Nano-titanium dioxide can improve the UV resistance of the modified sodium alginate layer, thereby reducing the photolysis of the active ingredients and the active ingredient microcapsules, so that the active ingredients can fully exert their effectiveness in the field.

[0028] 3. In this application, the addition amounts of active ingredients and nano-titanium dioxide are controlled so that the active ingredients can be effectively dispersed in the modified sodium alginate layer. At the same time, nano-titanium dioxide can not only effectively improve the protective effect of the modified sodium alginate layer on the active ingredients, but also be evenly dispersed in the modified sodium alginate layer. DETAILED DESCRIPTION

[0029] The present application is further described in detail below with reference to the embodiments.

[0030] Preparation Examples 1-16 of Active Ingredients

[0031] Preparation Example 1

[0032] The method for preparing active ingredient microcapsules comprises the following steps: dissolving 1 g of PHBV and an active ingredient in 5 mL of chloroform, adding the solution to 125 mL of water containing 3 mL of an emulsifier, Span80, while stirring, stirring and emulsifying, centrifuging, separating, washing, and freeze-drying to prepare active ingredient microcapsules, wherein the mass ratio of spironolactone, abamectin, and fluopicolide among the active ingredients is 1.12:0.67:0.95, and the mass ratio of PHBV to the active ingredient is 8.68:2.32;

[0033] Sodium alginate was dissolved in water to form a 10wt% sodium alginate solution, and the active ingredient and nano-titanium dioxide were added and dispersed evenly to form 500mL of a mixed solution. In the mixed solution, the amount of active ingredient added was 12.15wt% of sodium alginate, and the amount of nano-titanium dioxide added was 2.25wt% of sodium alginate. 4g of active ingredient microcapsules were added and stirred evenly, and then centrifuged and separated, and then dispersed into 200mL of 4wt% calcium chloride solution, stirred for 30min, allowed to stand for 1h, centrifuged, separated, and freeze-dried to obtain the active ingredient.

[0034] Preparation Example 2

[0035] The method for preparing active ingredient microcapsules comprises the following steps: dissolving 1 g of PHBV and an active ingredient in 5 mL of chloroform, adding the solution to 125 mL of water containing 3 mL of an emulsifier, Span80, while stirring, stirring and emulsifying, centrifuging, separating, washing, and freeze-drying to prepare active ingredient microcapsules, wherein the mass ratio of spironolactone, abamectin, and fluopicolide among the active ingredients is 1.28:0.81:1.21, and the mass ratio of PHBV to the active ingredient is 9.21:2.68;

[0036] Sodium alginate was dissolved in water to form a 10wt% sodium alginate solution, and the active ingredient and nano-titanium dioxide were added and dispersed evenly to form 500mL of a mixed solution. In the mixed solution, the amount of active ingredient added was 16.25wt% of sodium alginate, and the amount of nano-titanium dioxide added was 4.12wt% of sodium alginate. 4g of active ingredient microcapsules were added and stirred evenly, and then centrifuged and separated, and then dispersed into 200mL of 4wt% calcium chloride solution, stirred for 30min, allowed to stand for 1h, centrifuged, separated, and freeze-dried to obtain the active ingredient.

[0037] Preparation Example 3

[0038] The difference between Preparation Example 3 and Preparation Example 1 is that in Preparation Example 3, the mass ratio of spironol, abamectin and fluopicolide is 1.12:0.12:1.84.

[0039] Preparation Example 4

[0040] The difference between Preparation Example 4 and Preparation Example 1 is that in Preparation Example 4, the mass ratio of spironol, abamectin and fluopicolide is 1.12:1.68:0.25.

[0041] Preparation Example 5

[0042] The difference between Preparation Example 5 and Preparation Example 1 is that in Preparation Example 5, the mass ratio of PHBV to active ingredient is 8.68:1.12.

[0043] Preparation Example 6

[0044] The difference between Preparation Example 6 and Preparation Example 1 is that in Preparation Example 6, the mass ratio of PHBV to active ingredient is 8.68:3.68.

[0045] Preparation Example 7

[0046] The difference between Preparation Example 7 and Preparation Example 1 is that in Preparation Example 7, the amount of the active ingredient added is 5.68 wt % of the sodium alginate.

[0047] Preparation Example 8

[0048] The difference between Preparation Example 8 and Preparation Example 1 is that in Preparation Example 8, the amount of the active ingredient added is 24.35 wt % of the sodium alginate.

[0049] Preparation Example 9

[0050] The difference between Preparation Example 9 and Preparation Example 1 is that in Preparation Example 9, the added amount of nano-titanium dioxide is 1.12 wt % of sodium alginate.

[0051] Preparation Example 10

[0052] The difference between Preparation Example 10 and Preparation Example 1 is that in Preparation Example 10, the added amount of nano-titanium dioxide is 7.98 wt % of the sodium alginate.

[0053] Preparation Example 11

[0054] The difference between Preparation Example 11 and Preparation Example 1 is that in Preparation Example 11, the added amount of the active ingredient microcapsules is 1 g.

[0055] Preparation Example 12

[0056] The difference between Preparation Example 12 and Preparation Example 1 is that in Preparation Example 12, the added amount of the active ingredient microcapsules is 10 g.

[0057] Preparation Example 13

[0058] The difference between Preparation Example 13 and Preparation Example 1 is that in Preparation Example 13, an equal amount of spironolactone is used instead of the active ingredient.

[0059] Preparation Example 14

[0060] The difference between Preparation Example 14 and Preparation Example 1 is that in Preparation Example 14, an equal amount of avermectin is used instead of the active ingredient.

[0061] Preparation Example 15

[0062] The difference between Preparation Example 15 and Preparation Example 1 is that in Preparation Example 15, an equal amount of pentoquinoxaline is used instead of the active ingredient.

[0063] Preparation Example 16

[0064] The difference between Preparation Example 16 and Preparation Example 1 is that in Preparation Example 16, the active ingredient microcapsules are the effective ingredients, that is, there is no modified sodium alginate layer. Example

[0065] In the embodiments of the present application, the defoaming agent is the silicone defoaming agent of Foshan Nanhai Datian Chemical Co., Ltd., the preservative is sodium benzoate, the thickener is xanthan gum, and the dispersant is the wetting and dispersing aid of Shanghai Kaiyin Chemical Co., Ltd.

[0066] Example 1

[0067] A composition containing spironolactone comprises the following raw materials: 25 kg of active ingredient, 90 kg of water, 2 kg of dispersant, 0.2 kg of thickener, 0.3 kg of defoamer, and 0.2 kg of preservative, wherein the active ingredient is the active ingredient prepared in Preparation Example 1.

[0068] The preparation method of the above-mentioned spironolactone-containing composition comprises the following steps: adding a dispersant and a preservative to water, stirring at a speed of 700 r / min after uniformity, adding an active ingredient, dispersing at 500 r / min after uniformity, adding a thickener and a defoaming agent, and continuing to stir until uniformity to obtain a spironolactone-containing composition.

[0069] Example 2

[0070] A composition containing spironolactone comprises the following raw materials: 28 kg of active ingredient, 95 kg of water, 6 kg of dispersant, 0.3 kg of thickener, 0.4 kg of defoamer, and 0.1 kg of preservative, wherein the active ingredient is the active ingredient prepared in Preparation Example 2.

[0071] The preparation method of the above-mentioned spirothiazolinone-containing composition comprises the following steps: adding a dispersant and a preservative to water, stirring at a speed of 800 r / min until uniform, adding an active ingredient, dispersing at 600 r / min until uniform, adding a thickener and a defoaming agent, and continuing to stir until uniform to obtain a spirothiazolinone-containing composition.

[0072] Example 3

[0073] The difference between Example 3 and Example 1 is that in Example 3, the active ingredient is the active ingredient prepared in Preparation Example 3.

[0074] Example 4

[0075] The difference between Example 4 and Example 1 is that in Example 4, the active ingredient is the active ingredient prepared in Preparation Example 4.

[0076] Example 5

[0077] The difference between Example 5 and Example 1 is that in Example 5, the active ingredient is the active ingredient prepared in Preparation Example 5.

[0078] Example 6

[0079] The difference between Example 6 and Example 1 is that in Example 6, the active ingredient is the active ingredient prepared in Preparation Example 6.

[0080] Example 7

[0081] The difference between Example 7 and Example 1 is that in Example 7, the active ingredient is the active ingredient prepared in Preparation Example 7.

[0082] Example 8

[0083] The difference between Example 8 and Example 1 is that in Example 8, the active ingredient is the active ingredient prepared in Preparation Example 8.

[0084] Example 9

[0085] The difference between Example 9 and Example 1 is that in Example 9, the active ingredient is the active ingredient prepared in Preparation Example 9.

[0086] Example 10

[0087] The difference between Example 10 and Example 1 is that in Example 10, the active ingredient is the active ingredient prepared in Preparation Example 10.

[0088] Example 11

[0089] The difference between Example 11 and Example 1 is that in Example 11, the active ingredient is the active ingredient prepared in Preparation Example 2.

[0090] Example 12

[0091] The difference between Example 12 and Example 1 is that in Example 12, the active ingredient is the active ingredient prepared in Preparation Example 12.

[0092] Example 13

[0093] The difference between Example 13 and Example 1 is that in Example 13, the active ingredient is the active ingredient prepared in Preparation Example 13.

[0094] Example 14

[0095] The difference between Example 14 and Example 1 is that in Example 14, the active ingredient is the active ingredient prepared in Preparation Example 14.

[0096] Example 15

[0097] The difference between Example 15 and Example 1 is that in Example 15, the active ingredient is the active ingredient prepared in Preparation Example 15.

[0098] Comparative Example

[0099] Comparative Example 1

[0100] The difference between Comparative Example 1 and Example 1 is that in Comparative Example 1, the active ingredient is the active ingredient prepared in Preparation Example 16.

[0101] Test methods

[0102] According to the method of Examples 1-15 and Comparative Example 1, an effective ingredient was prepared, and a field efficacy test was carried out together with a blank control group of clear water. Each embodiment, comparative example or control group was treated 3 times, with a total of 51 treatment plots. Cucumber seedlings were selected as plants, and root irrigation treatment was carried out at the early stage of root knot nematode disease. The effective ingredient dosage was 0.6 g / L, and the dosage per plant was 250 mL. The root knot condition of cucumber root knot nematode disease was investigated 1d, 7d, and 15d after the drug was applied. Three points were randomly selected from each plot, and three cucumber seedlings were investigated at each point. The root knot condition grading standard was as follows: no root knot visible to the naked eye was grade 0, 1 %-20% of the roots with root knots are graded as 1, 21%-40% of the roots with root knots are graded as 2, 41%-60% of the roots with root knots are graded as 3, 61%-80% of the roots with root knots are graded as 4, and more than 80% of the roots with root knots are graded as 5. The control effect is calculated and the results are recorded in Table 1. The calculation formula for the control effect is: Control effect (%) = (control disease index - treatment disease index) / control disease index × 100%. The calculation formula for the disease index is: Disease index (%) = (Σnumber of diseased plants at each disease level × number of disease levels) / (total number of plants surveyed × number of the highest level) × 100%.

[0103] Table 1 Control effect

[0104] project 1d after medication / % 7d after medication / % 15d after medication / % Example 1 90.32 95.25 98.35 Example 2 91.24 95.92 98.81 Example 3 86.16 88.61 90.15 Example 4 87.68 89.84 91.19 Example 5 85.91 89.24 90.37 Example 6 86.51 88.61 91.81 Example 7 87.20 87.15 92.62 Example 8 85.15 89.45 91.15 Example 9 87.37 90.15 92.92 Example 10 86.35 89.09 90.52 Example 11 82.15 88.51 92.15 Example 12 83.25 87.35 91.67 Example 13 82.15 84.51 86.25 Example 14 81.35 83.62 87.37 Example 15 83.91 84.17 86.81 Comparative Example 1 75.26 81.65 89.15

[0105] According to Examples 1-2 and Comparative Example 1, it can be seen that Examples 1-2 have a better control effect, and still have a better control effect 15 days after a single application. While effectively controlling cucumber root knot nematode disease, it can reduce the application amount and the number of applications, thereby reducing pollution to the environment. In Examples 1-2, PHBV is used to coat the active ingredient, which protects the active ingredient from oxygen and water, and can also achieve a certain degree of light-shielding effect. After the composition is applied, it is decomposed by environmental microorganisms and exposed to light in the field, and PHBV can provide protection for it. The modified sodium alginate layer quickly decomposes to provide rapid initial protection for the cucumber, and the active ingredient microcapsules remain in the field and continuously release the active ingredient to achieve long-term protection, thereby comprehensively achieving the control of cucumber root knot nematode disease, while reducing the number of applications of the composition, extending the application cycle, and reducing pollution to the environment.

[0106] The active ingredient in Comparative Example 1 does not have a modified sodium alginate layer, which reduces the initial control effect of Comparative Example 1. At the same time, the control effect 15 days after the application is also reduced. After the active ingredient microcapsule is applied, the sustained release of the active ingredient is restricted, which reduces the initial drug amount, which is not conducive to the initial control effect. In addition, the loss of the protection of the modified sodium alginate layer shortens the sustained release period of the active ingredient microcapsule, which also reduces the control effect 15 days after the application.

[0107] Compared with Example 1-2, the control effects of Examples 3-4 and 13-15 are reduced, indicating that changes in the mass ratio of a single drug or the three can easily lead to a decrease in the control effect of the active ingredient, which fully demonstrates that there is a synergistic control effect between spirothiazolin, abamectin and fluopicolide, which can effectively improve the control effect of cucumber root knot nematode disease, thereby effectively reducing the number of applications and extending the application cycle.

[0108] Compared with Example 1-2, the control effect of Example 5-12 is reduced. When preparing the active ingredient microcapsules of Example 5-6, the mass ratio of PHBV to the active ingredient was changed. When preparing the active ingredients of Examples 7-8, the amount of active ingredient added in the modified sodium alginate layer was changed. When preparing the active ingredients of Examples 9-10, the amount of nano-titanium dioxide added in the modified sodium alginate layer was changed. When preparing the active ingredients of Examples 11-12, the amount of active ingredient microcapsules added was changed. This shows that the capsule-core ratio of the active ingredient microcapsules, the active ingredient content in the modified sodium alginate layer, the amount of nano-titanium dioxide added, and the coating thickness of the modified sodium alginate layer will affect the efficacy of the active ingredient and the composition.

[0109] The capsule-core ratio of the active ingredient microcapsules directly affects the sustained-release rate of the active ingredient, resulting in the active ingredient being released too quickly or too slowly, which makes it impossible to cover the growth cycle of the plant and achieve stable and long-term control. The content of the active ingredient in the modified sodium alginate layer directly affects the control effect in the early stage after the application of the drug. If the addition amount is too small, the control effect will appear too slowly, and the initial control effect will be poor. If the addition amount is too large, residues will easily appear, and the control effect will not be significantly improved. The addition amount of nano-titanium dioxide directly affects the UV resistance of the active ingredient, which in turn affects its photolysis rate and causes loss of the active ingredient. The coating thickness of the modified sodium alginate layer affects the degradation cycle of the modified sodium alginate layer, thereby advancing or delaying the action cycle of the active ingredient microcapsules, which is not conducive to matching the action cycle of the composition with the growth cycle of cucumbers.

[0110] This specific embodiment is merely an explanation of the present application and is not a limitation of the present application. After reading this specification, those skilled in the art may make non-creative modifications to the present embodiment as needed, but as long as they are within the scope of the claims of the present application, they are protected by the patent law.

Claims

1. A composition containing spirothracenyl, characterized in that: The invention comprises the following raw materials in parts by mass: 25-28 parts of active ingredients, 90-95 parts of water, 2-6 parts of dispersants, 0.1-0.5 parts of thickeners, 0.1-0.5 parts of defoamers, and 0.1-0.3 parts of preservatives. The active ingredients are active ingredient microcapsules coated with a modified sodium alginate layer, the capsule walls of the active ingredient microcapsules are PHBV, and the capsule cores are active ingredients. The active ingredients include spirotriflate, avermectin, and fluopicolide. The preparation method of the active ingredients comprises the following steps: dissolving sodium alginate in water to form a sodium alginate solution, adding the active ingredients and nano-titanium dioxide, and uniformly dispersing them to form a mixed solution, adding the active ingredient microcapsules, stirring evenly, centrifuging and separating, and then dispersing the mixed solution into a calcium chloride solution, stirring for 30 minutes, standing for 1 hour, centrifuging, separating, and freeze-drying to obtain the active ingredients.

2. A composition containing spirothracenyl according to claim 1, characterized in that: Among the active ingredients, the mass ratio of spironolactone, abamectin and fluopicolide is (1.12-1.28):(0.67-0.81):(0.95-1.21).

3. A composition containing spirothracenyl according to claim 1, characterized in that: The preparation method of the active ingredient microcapsules comprises the following steps: dissolving PHBV and the active ingredient in chloroform, adding the mixture to water containing an emulsifier while stirring, stirring and emulsifying, centrifuging, separating, washing, and freeze-drying to obtain the active ingredient microcapsules.

4. A composition containing spirothracenyl according to claim 3, characterized in that: The mass ratio of PHBV to active ingredient is (8.68-9.21):(2.32-2.68).

5. A composition containing spironolactone according to claim 1, characterized in that: The amount of the active ingredient added is 12.15-16.25 wt % of the sodium alginate, and the amount of nano titanium dioxide added is 2.25-4.12 wt % of the sodium alginate.

6. A composition containing spironolactone according to claim 1, characterized in that: Before adding the active ingredient microcapsules to the mixed solution, a silane coupling agent is further added, and the amount of the silane coupling agent added is 10.32-12.58 wt % of the mixed solution.

7. The method for preparing a composition containing spirothiazolinone according to any one of claims 1 to 6, wherein: The method comprises the following steps: adding a dispersant and a preservative into water, stirring the mixture evenly, adding an effective ingredient, dispersing the ingredient evenly, adding a thickener and a defoaming agent, and continuing stirring the mixture until the mixture is evenly distributed to obtain a composition containing spironolactone.

8. Use of a composition containing spirothracenyl according to any one of claims 1 to 6 in preventing and treating cucumber root-knot nematode disease.